(Q35688221)

9 August 2017

1 reference

title

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? (English)

1 reference

9 August 2017

author name string

Harrihar A Pershadsingh

series ordinal

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

published in

1 reference

9 August 2017

volume

13

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

215-228

1 reference

The nuclear receptor superfamily: the second decade

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Emerging roles of PPARs in inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Atherosclerosis. the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Transcription-modulating drugs: a new frontier in the treatment of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Therapeutic potential of thiazolidinediones as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Muscle-specific Pparg deletion causes insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Differentiating members of the thiazolidinedione class: a focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Insulin stimulates both endothelin and nitric oxide activity in the human forearm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

The perils of portliness: causes and consequences of visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Therapeutic potential of angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF‐κβ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

New drug targets for type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Obesity, adiponectin and vascular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

CD40 signaling and plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Improvement of asthma after administration of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

Recent advances in angiotensin II signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.215

10.1517/13543784.13.3.215

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference